# OnCo record xcovery (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/xcovery/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "xcovery" ;
  schema:name "Xcovery"@en ;
  schema:alternateName "Xcovery Holdings, Inc."@en ;
  schema:description "Xcovery is the Florida company that developed ensartinib, an ALK inhibitor approved by the FDA in December 2024 for ALK-positive non-small-cell lung cancer, partnered with Betta Pharmaceuticals in China where it was approved first."@en ;
  schema:url <https://onco.cc/companies/xcovery/>, <https://www.xcovery.com/> ;
  schema:dateModified "2026-09-11"^^xsd:date ;
  schema:citation <https://www.xcovery.com/>, <https://www.fda.gov/drugs/resources-information-approved-drugs/oncology-cancer-hematologic-malignancies-approval-notifications> ;
  onco:tag "fda-oce-applicant" ;
  schema:addressCountry "US" ;
  onco:cancers <https://onco.cc/cancers/nsclc/> ;
  onco:sections <https://onco.cc/fronts/targeted-therapy/> ;
  onco:drugs <https://onco.cc/drugs/ensartinib/> ;
  onco:trials <https://onco.cc/trials/nct02767804/> .